Philip D. Hall

903 citations

32 papers · 712 indexed · h-index 17

Biotechnology top 5%
- Transgenic Plants and Applications 13
- Microbial Inactivation Methods 4
Immunology top 10%
- Toxin Mechanisms and Immunotoxins 18
- Immune Cell Function and Interaction 3
Hematology top 10%
- Acute Myeloid Leukemia Research 2
Oncology
- CAR-T cell therapy research 3
Clinical Biochemistry
Neurology
- Neuroblastoma Research and Treatments 4
Genetics
- Virus-based gene therapy research 2

Co-authors: Arthur E. Frankel Robert J. Kreitman Mark C. Willingham Edward P. Tagge Bayard L. Powell L. Douglas Case Tie Fu Liu John B. Bossaer
Cited by: Biotechnology Immunology Hematology
Partner nations: United States Canada Australia

In The Last Decade

Philip D. Hall

32 papers receiving 702 citations

Peers

Replace J.M.C. Wessels with:

J.M.C. Wessels Netherlands

R. Schnell Germany

Oettgen Hf United States

Ulrich Mack Germany

Cydney Urbanek United States

S Okamura Japan

A M Kaplan United States

C. A. Savary United States

H. Pandha United Kingdom

R. N. Taub United States

Philip D. Hall relative to J.M.C. Wessels Netherlands J.M.C. Wessels's profile →

Citations per field

00.5×2×4×6×8×

J.M.C. Wessels · 1×

×3.1 196/64

BIOTE

×2.6 384/145

IMMUN

×0.8 87/116

HEMAT

×2.5 193/76

ONCOL

×7.8 31/4

CB

Citations per year

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

Countries citing papers authored by Philip D. Hall

Since Specialization

Citations

This map shows the geographic impact of Philip D. Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip D. Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip D. Hall more than expected).

Fields of papers citing papers by Philip D. Hall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip D. Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip D. Hall. The network helps show where Philip D. Hall may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Philip D. Hall, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Philip D. Hall Line = papers co-authored together Philip D. Hall links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Report of the 2012-2013 Standing Committee on Advocacy: Advocacy Tools and Resources: A Framework for Increasing Member Engagement Marie Smith,Hershey S. Bell,Julie C. Kissack,Philip D. Hall,George E. MacKinnon,William Lang	2013	3
2	Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE John B. Bossaer,Philip D. Hall,Elizabeth Garrett‐Mayer	2010	45
3	Single‐Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults Anne McDonnell,Kristi L Lenz,Debra Frei‐Lahr,John Hayslip,Philip D. Hall	2006	60
4	Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: implications for diphtheria fusion protein therapy Philip D. Hall,Debajyoti Sinha,Arthur E. Frankel	2006	2
5	Toxicology and Pharmacokinetics of DT₃₈₈IL3, a Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT₃₈₈) Linked to Human Interleukin 3 (IL3), in Cynomolgus Monkeys Kimberley A. Cohen,Tie Fu Liu,J. Mark Cline,Janice D. Wagner,Philip D. Hall,Arthur E. Frankel	2004	27
6	Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey Kimberley A. Cohen,Tie Fu Liu,J. Mark Cline,Janice D. Wagner,Philip D. Hall,Arthur E. Frankel	2004	24
7	Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials Jeffrey O Urieto,TieFu Liu,J Black,Kimberley A. Cohen,Philip D. Hall,Mark C. Willingham,Lewis K Pennell,Donna E. Hogge,Robert J. Kreitman,Arthur E. Frankel	2003	35
8	The Majority of Children and Adolescents With Acute Myeloid Leukemia Have Detectable Anti-DT388-GMCSF IgG Concentrations, but at Concentrations That Should Not Preclude In Vivo Activity Philip D. Hall,Bassem I. Razzouk,Tony E. Willoughby,Thomas W. McLean,Arthur E. Frankel	2002	2
9	High-Level Expression and Purification of the Recombinant Diphtheria Fusion Toxin DTGM for PHASE I Clinical Trials Arthur E. Frankel,Jason G. Ramage,Amy Latimer,Theodore Feely,Stephen J. Delatte,Philip D. Hall,Edward P. Tagge,Robert J. Kreitman,Mark C. Willingham	1999	28
10	Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells Caryn N. Kim,Kapil N. Bhalla,Robert J. Kreitman,Mark C. Willingham,Philip D. Hall,Edward P. Tagge,Tao Jia,Authur E Frankel	1999	22
11	Toxicology and Pharmacokinetics of DTGM, a Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT388) Linked to Human Granulocyte-Macrophage Colony-Stimulating Factor, in Cynomolgus Monkeys Charlotte E. Hotchkiss,Philip D. Hall,J. Mark Cline,Mark C. Willingham,Robert J. Kreitman,Jean F. Gardin,Amy Latimer,Jason G. Ramage,Theodore Feely,Stephen J. Delatte,Edward P. Tagge,Arthur E. Frankel	1999	20
12	Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Arthur E. Frankel,Michelle M. Lilly,Robert J. Kreitman,Donna E. Hogge,Miloslav Beran,Melvin H. Freedman,Peter D. Emanuel,Chris McLain,Philip D. Hall,Edward P. Tagge,Marc Berger,Connie J. Eaves	1998	30
13	Toxicology and Pharmacokinetics of DT388-GM-CSF, a Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT388) Linked to Human Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in C57BL/6 Mice Philip D. Hall,R. J. Kreitman,Mark C. Willingham,Arthur E. Frankel	1998	11
14	Cell-Specific Modulation of Drug Resistance in Acute Myeloid Leukemic Blasts by Diphtheria Fusion Toxin, DT388-GMCSF Arthur E. Frankel,Philip D. Hall,Chris McLain,Ahmad R. Safa,Edward P. Tagge,Robert J. Kreitman	1998	26
15	Synthesis of Green Fluorescent Protein−Ricin and Monitoring of Its Intracellular Trafficking Edward P. Tagge,Billie Harris,Chris Burbage,Philip D. Hall,Joseph Vesely,Mark C. Willingham,Arthur E. Frankel	1997	8
16	The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Philip D. Hall,H Benko,Kathryn Hogan,Robert K. Stuart	1995	32
17	Immunomodulation With Intravenous Immunoglobulin Philip D. Hall	1993	19
18	Head and Neck Cancer: Detection and Therapeutics Philip D. Hall,Jim M. Koeller	1990	4
19	The Effect of Everyday Exercise on Steady State Digoxin Concentrations Philip D. Hall,William R. Garnett,Kenneth W. Kolb,William L. Rock,Holly Stanley	1989	4
20	Halothane hepatitis in an animal model: time course of hepatic damage. K. M. Knights,G. K. Gourlay,Philip D. Hall,John Adams,Michael J. Cousins	1987	8

About Philip D. Hall

Philip D. Hall is a scholar working on Biotechnology, Immunology and Hematology, having authored 32 papers that have together received 712 indexed citations. Recurring topics across this work include Toxin Mechanisms and Immunotoxins (18 papers), Transgenic Plants and Applications (13 papers), Neuroblastoma Research and Treatments (4 papers), Microbial Inactivation Methods (4 papers), CAR-T cell therapy research (3 papers), Immune Cell Function and Interaction (3 papers), Acute Myeloid Leukemia Research (2 papers) and Virus-based gene therapy research (2 papers). The work is most often cited by research in Biotechnology (196 citations), Immunology (384 citations) and Hematology (87 citations). Philip D. Hall has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Arthur E. Frankel, Robert J. Kreitman, Mark C. Willingham, Edward P. Tagge, Bayard L. Powell, L. Douglas Case, Arthur E. Frankel, Tie Fu Liu, John B. Bossaer and Elizabeth Garrett‐Mayer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact